Bayer says menopause drug succeeds in breast cancer study
The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...
FierceBiotech2d
Bayer makes hot flash splash, hitting phase 3 breast cancer goal to steal march on Astellas
Thursday, Bayer shared top-line data from a phase 3 trial that tested elinzanetant in women on adjuvant endocrine therapy for ...
Bayer menopause drug reduces hot flashes in breast cancer group
Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the ...
Bayer attacked bureaucracy by firing some 5,000 managers and asking teams to ‘self-organize.’ Here’s how it’s going after one year
Whether ahead of their time, truly bizarre, or just plain doomed, it’s certainly interesting to see companies go completely ...
Bayer: Sell And Be Done With It
Bayer's projected earnings decline and litigation pressures affect its outlook. Find out why BAYRY stock might face ...
Bayer's Elinzanetant Meets Primary, Secondary Endpoints In Phase III OASIS 4 Breast Cancer Study
(RTTNews) - Bayer Aktiengesellschaft (BAYRY.PK), Thursday announced that Elinzanetant, a non-hormonal drug, has met all primary and second endpoints in the Phase III study OASIS 4, investigating the ...
Pharmabiz1d
Bayer’s subsidiary, Vividion acquires Tavros Therapeutics to expand functional genomics capabilities and boost drug discovery platform
San Diego, California Friday, January 10, 2025, 10:00 Hrs [IST] ...
Wall Street Journal25d
Bayer’s Eye Drug Shows Positive Results in Late-Stage Trial
Bayer BAYN0.33%increase ... Patients received 8 milligrams of the drug every eight weeks and achieved visual acuity gains after 36 weeks. The treatment led to rapid, robust reduction of fluid ...